Be a Smart Investor
Wednesday, June 15, 2016
Infinity Pharmaceuticals Inc. (INFI) Sank To A New Low On Phase 2 Study News
Infinity Pharmaceuticals Inc. (INFI) announced Tuesday morning that its Phase 2 study of duvelisib its primary endpoint of overall response rate.
from RTT - Before the Bell http://ift.tt/1Yrqfhv
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment